JESSICA MAIZEL: Open Payments
NPI 1891357638 · HALETHORPE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,028 in 49 payments from 13 companies in 2025. Trend: 2023 $999 · 2024 $754 · 2025 $1,028
Food & beverage: $1,028
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $139 |
| Neurocrine BioSciences, Inc. | 6 | $138 |
| Lundbeck LLC | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Alkermes, Inc. | 3 | $62 |
| Almatica Pharma LLC | 2 | $55 |
| Tris Pharma Inc | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, REXULTI, HETLIOZ, ARISTADA, LOREEV XR, Dyanavel XR.
Industry payments across MD — which companies pay providers there.
